Search Results - christoph+rader

4 Results

Sort By:

Antibody Targeting of Cell Surface Deposited Complement Protein C3d as a Treatment for Cancer

This technology includes monoclonal antibodies (mAb) that specifically and with high affinity bind the final complement components C3dg and C3d (subsequently referred to as C3d), which can be used to kill tumor cells that carry C3d on their cell surface. We show that tumor cells of patients treated with the therapeutic anti-CD20 mAb ofatumumab carry...

Published: 8/12/2024 | Inventor(s): Martin Skarzynski, Adrian Wiestner, Margaret Lindorfer, Ronald Taylor, Christoph Rader, Berengere Vire

Keywords(s):

Category(s): Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Antibodies, TherapeuticArea > Oncology

Enhancing Activity of Bispecific Antibodies in Combination with Ibrutinib for the Treatment of Cancer

This technology includes the combination of a kinase inhibitor (specifically ibrutinib) with a bispecific antibody (specifically a CD19/CD3 bispecific antibody) to be used to treat cancer. CD19/CD3 bispecific antibodies (bsAbs) can be used to recruit endogenous T cells against CD19+ tumor cells via the formation of cytolytic synapses. lbrutinib, a BTK...

Published: 8/12/2024 | Inventor(s): Adrian Wiestner, Sivasubramanian Baskar, Christoph Rader

Keywords(s):

Category(s): Application > Research Materials, Collaboration Sought > Licensing, TherapeuticArea > Oncology

B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia

Abstract: B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes. Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST). However, there is less than a 50% chance of finding a matching...

Published: 8/14/2024 | Inventor(s): Christoph Rader, Sivasubramanian Baskar, Jessica Suschak, Ivan Samija, Michael Bishop

Keywords(s): alloHSCST, B-CELL, Leukemia, Lymphocytic

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Licensing

Potentiating Antibody Therapy by Targeting Complement Deposited on Cancer Cells

Monoclonal antibodies (mAbs) have become a mainstay of therapy for many cancers. However, antibody therapy is not completely effective in some applications due to loss of the target surface antigen on cancer cells. Such mAb-induced “escape variants” are no longer sensitive to the therapeutic mAb therapy. It was observed that the escape variants carried...

Published: 7/25/2024 | Inventor(s): Martin Skarzynski, Margaret Lindorfer, Ronald Taylor, Christoph Rader, Berengere Vire, Erika Gaglione, Haiyong Peng, Sivasubramanian Baskar, Adrian Wiestner

Keywords(s): 2JXXXX, 4GXXXX, 5OXXXX, ANTIBODY, C3, C3d, CANCER, CB1XXX, Cell, Cells, Complement, Deposited, Listed LPM Vathyam as of 4/15/2015, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Potentiating, Pre LPM working set 20150418, Protein, Surface, Targeting, THERAPY, THEROF, VCXXXX

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Immunology